Company Overview of Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pha...
332 East Scott Street
Port Hueneme, CA 93041
Key Executives for Stellar Biotechnologies, Inc.
Chairman, Chief Executive Officer and President
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secretary
Total Annual Compensation: $175.0K
Chief Operating Officer
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.
Stellar Biotechnologies, Inc. Key Developments
Stellar Biotechnologies, Inc. and Amaran Biotechnology Inc. Provide Update on Collaboration
Oct 1 15
Stellar Biotechnologies, Inc. provided an update on the company's ongoing collaboration with Amaran Biotechnology, Inc. The alliance between Stellar and Amaran was formed in 2013 to develop and evaluate methods for the manufacture of the OBI-822 immunotherapy, which incorporates Stellar KLHTM as the immune-stimulating carrier molecule. Stellar and Amaran have now completed all primary objectives of the collaboration, which include method development, formulation, and process qualification for GMP-grade Stellar KLHTM and meeting the specifications needed for the production of OBI-822. The next stage of the collaboration will involve scale-up and optimization of processes to commercial manufacturing levels, with the focus on production, quality, and regulatory requirements to support OBI Pharma's planned global Phase III trial and potential future market launch.
Stellar Biotechnologies, Inc. Proposes Amendment to the By-Laws
Sep 15 15
Stellar Biotechnologies, Inc. proposed an amendment to the company's articles (by-laws) to amend certain corporate governance requirements in connection with the company's application for up-listing to The NASDAQ Capital Market (NASDAQ), at its special meeting of shareholders of the company will be held on October 29, 2015.
Stellar Biotechnologies, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015
Aug 10 15
Stellar Biotechnologies, Inc. announced consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported total revenue of USD 157,748, net income of USD 463,986 or USD 0.01 per basic and diluted share against the total revenue was USD 72,538, net income was USD 3,408,326 or USD 0.04 per basic and diluted share a year ago. Revenue was driven primarily by an increase in product sales period-over-period. The year-over-year decrease in net income was primarily due to fluctuations in noncash gains in the fair value of warrant liability, increased revenue and decreased research and development expenses.
For the nine months, the company reported total revenue of USD 558,036, net loss of USD 1,305,655 or USD 0.02 per basic and diluted share against the total revenue was USD 245,734, net income was USD 3,602,718 or USD 0.05 per basic and diluted share a year ago. The period-over-period decrease in net loss was primarily due to significant noncash gains in the fair value of warrant liability, increased revenues and decreased research and development expenses, net of increased noncash foreign exchange loss. Net cash used in operating activities of USD 3,497,293 compared to USD 3,660,304 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|